Highwater Wealth Management LLC bought a new position in Johnson & Johnson (NYSE:JNJ) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 1,999 shares of the company’s stock, valued at approximately $264,000.

A number of other hedge funds have also recently modified their holdings of the stock. Lenox Wealth Advisors Inc. lifted its position in Johnson & Johnson by 0.7% in the first quarter. Lenox Wealth Advisors Inc. now owns 871 shares of the company’s stock worth $108,000 after purchasing an additional 6 shares during the period. Lbmc Investment Advisors LLC lifted its position in Johnson & Johnson by 0.4% in the first quarter. Lbmc Investment Advisors LLC now owns 3,704 shares of the company’s stock worth $461,000 after purchasing an additional 14 shares during the period. Berson & Corrado Investment Advisors LLC lifted its position in Johnson & Johnson by 0.7% in the first quarter. Berson & Corrado Investment Advisors LLC now owns 2,835 shares of the company’s stock worth $353,000 after purchasing an additional 19 shares during the period. RB Capital Management LLC lifted its position in Johnson & Johnson by 0.4% in the first quarter. RB Capital Management LLC now owns 5,559 shares of the company’s stock worth $692,000 after purchasing an additional 24 shares during the period. Finally, Keel Point LLC lifted its position in Johnson & Johnson by 0.4% in the first quarter. Keel Point LLC now owns 6,402 shares of the company’s stock worth $797,000 after purchasing an additional 24 shares during the period. 65.90% of the stock is owned by hedge funds and other institutional investors.

Several research analysts recently commented on JNJ shares. BidaskClub raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 17th. Royal Bank Of Canada reissued a “buy” rating and set a $128.00 price objective on shares of Johnson & Johnson in a report on Thursday, June 15th. Atlantic Securities cut Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 price objective for the company. in a report on Friday, July 21st. Jefferies Group LLC reissued a “hold” rating and set a $145.00 price objective (up from $140.00) on shares of Johnson & Johnson in a report on Friday, July 14th. Finally, Morgan Stanley lifted their price objective on Johnson & Johnson from $135.00 to $140.00 and gave the company an “overweight” rating in a report on Wednesday, July 5th. Five investment analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have issued a buy rating to the stock. Johnson & Johnson presently has an average rating of “Hold” and a consensus price target of $135.29.

In other news, VP Dominic J. Caruso sold 82,591 shares of the firm’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the completion of the transaction, the vice president now directly owns 226,693 shares in the company, valued at $30,993,466.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Paulus Stoffels sold 102,692 shares of the firm’s stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the transaction, the vice president now owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The disclosure for this sale can be found here. 0.19% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another domain, it was copied illegally and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.dailypolitical.com/2017/09/22/highwater-wealth-management-llc-takes-264000-position-in-johnson-johnson-jnj.html.

Johnson & Johnson (JNJ) traded down 0.1661% during trading on Friday, hitting $131.5312. The stock had a trading volume of 1,579,699 shares. The company has a 50-day moving average of $132.79 and a 200 day moving average of $129.44. The company has a market cap of $353.03 billion, a price-to-earnings ratio of 22.2557 and a beta of 0.79. Johnson & Johnson has a 52 week low of $109.32 and a 52 week high of $137.08. Johnson & Johnson also saw unusually large options trading on Wednesday. Stock investors purchased 11,192 put options on the company. This represents an increase of 244% compared to the average daily volume of 3,249 put options.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The company had revenue of $18.84 billion during the quarter, compared to the consensus estimate of $18.94 billion. During the same period last year, the company earned $1.74 earnings per share. The firm’s revenue was up 1.9% compared to the same quarter last year. On average, equities research analysts anticipate that Johnson & Johnson will post $7.18 EPS for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th were given a dividend of $0.84 per share. The ex-dividend date of this dividend was Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.52%. Johnson & Johnson’s dividend payout ratio (DPR) is 56.76%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.